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Abstract 
Understanding cancer cell immortality in primary glioblastoma (GBM) is essential for the development 
of more informed treatments. Multiple cancer types, including >80% of GBMs, undergo 
immortalization by reactivating Telomerase Reverse Transcriptase (TERT) through acquired 
mutations in the TERT promoter. TERT, the catalytically active and rate-limiting subunit of 
telomerase, functions to maintain telomeres, which cap and protect the ends of chromosomes. Our 
past work has demonstrated that the transcription factor GABP - and specifically its tetramer-forming 
isoform GABPb1L - binds and activates the mutant TERT promoter. The generation of CRISPR-
induced indels in GABPb1L results in a gradual loss of cell viability in TERT promoter mutant but not 
TERT promoter wild type tumor cells in vitro, but the extent to which GABPb1L function is 
compromised in this setting is unclear. Thus, the potential for use of GABPb1L as an effective 
therapeutic target for TERT promoter mutant GBM requires further investigation. Here, we use 
CRISPR-based strategies to demonstrate that full knockout of GABPb1L is rapidly lethal in TERT 
promoter mutant cells in vitro, in association with a decrease in both TERT mRNA and telomerase 
activity. Heterozygous deletion of GABPb1L in the context of TERT promoter mutations leads to 
slowed growth of orthotopic xenograft tumors in mice, and prolonged survival. Additionally, inducible 
RNAi-mediated inhibition of GABPb1L in growing tumors is also capable of decreasing tumor burden 
and increasing survival, further strongly suggesting that targeting GABPb1L in patient tumors could 
be a viable treatment strategy. Finally, reduced GABPb1L synergizes with temozolomide (TMZ) 
therapy such that TMZ treatment in the context of low GABPb1L and low TERT leads to a complete 
ablation of orthotopic GBM xenografts. These results highlight the potential to improve disease 
outcomes by targeting TERT through inhibition of GABPb1L, particularly in conjunction with TMZ 
treatment. 
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